ImmunyX is a drug development company focused on creating novel pharmacological approaches for neutrophil modulation in disease. The company addresses the challenge of modulating neutrophil activity, which is implicated in numerous large market diseases like COPD, cancer, and arthritis. Their technology aims to provide safe and effective treatments by preventing deregulated neutrophil damage at the target location.
Funding
$30K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Uncontrolled neutrophil activity contributes to the pathology of various chronic diseases, including COPD, cancer, colitis, and arthritis. Current approaches to neutrophil modulation face challenges such as systemic toxicity, difficulty in targeted delivery, and the risk of neutropenia. The lack of approved neutrophil-targeting therapies leaves a significant unmet need for safe and effective treatments.
Solution
Immunyx is developing targeted nanoparticle therapeutics designed to selectively modulate neutrophil function in chronic diseases. Their technology aims to address the limitations of existing neutrophil therapies by delivering pharmacological agents directly to the site of neutrophil activity, minimizing systemic exposure and potential side effects. By precisely modulating neutrophil behavior, Immunyx seeks to reduce neutrophil-mediated damage in diseases like COPD, cancer, colitis, and arthritis, offering a novel approach to immune modulation. This targeted approach aims to improve efficacy and safety compared to traditional methods.
Target Audience
The primary target audience includes patients suffering from chronic diseases characterized by excessive neutrophil activity, such as COPD, cancer, colitis, and arthritis.
Features
- Targeted nanoparticles for selective delivery of therapeutic agents to neutrophils
- Modulation of neutrophil activity to reduce inflammation and tissue damage
- Development of therapies for COPD, cancer, colitis, and arthritis
- Pharmacological approach to neutrophil modulation